ITW

MAR 0 9 2007 W

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the seperwork Reductions of 1995, no per		t and Trademark Office; U.S. DEPARTMENT OF COMMERCI n of information unless it displays a valid OMB control numbe									
TRADEAMST.	Application Number	10/815,449									
TRANSMITTAL	Filing Date	4/1/04									
FORM	First Named Inventor	Yvo Graus									
(to be used for all correspondence after initial filing)	Art Unit	1614									
	Examiner Name										
Total Number of Pages in This Submission	Attorney Docket Number	21655 US2									
ENCLOSURES (Check all that apply)											
Fee Transmittal Form Fee Attached	Drawing(s) Licensing-related Papers	After Allowance communication to Group Appeal Communication to Board of Appeals and Interferences									
Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Terminal Disclaimer Request for Refund CD, Number of CD(s) marks cited art	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):									
SIGNATUR	E OF APPLICANT, ATTORNE	EY, OR AGENT									
Firm or Individual name Signature Date Mar. 7, 2007											
CERTI	FICATE OF TRANSMISSION	MAILING									
		deposited with the United States Postal Service with ents, P.O. Box 1450, Alexandria, VA 22313-1450 on									
Typed or printed name David E. Wild	man // //										
Signature		Date Mar. 7, 2007									

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT APPLICATION



In re Patent Application

Inventor(s) Graus et al

Group: 1614

Application No. 10/815,449, filed Apr. 1, 2004

Examiner:

(Case Docket No. 21655 US2)

For: ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR AND USES THEREOF

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 March 7, 2007

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A2, and B4-B5 listed on Form PTO-1449 are enclosed.

Enclosed is a Search Report, dated December 22, 2006, which was issued by the Austrian Patent Office in the 200506244-3 application corresponding to the captioned application. The Search Report lists Documents A2, and B4-B5.

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted after the first Office Action on the merits and after three months of the filing date for the captioned application, there is enclosed a Certificate under 37 C.F.R. § 1.97(e).

Respectfully submitted,

Attorney for Applicant(s)

David E. Wildman (Reg. No. 40226) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-6385 Telefax: (973) 235-2363

285531





In re Patent Application

Graus et al

Group: 1614

Application No. 10/815,449, filed Apr. 1, 2004

Examiner:

(Case Docket No. 21655 US2)

For: ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR AND USES THEREOF

STATEMENT UNDER 37 CFR § 1.97(e)

Nutley, New Jersey 07110 March 7, 2007

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify:

X That each item of information contained in the enclosed Information Disclosure
Statement was cited in a communication from a foreign patent office in a
counterpart foreign application not more than three months prior to the filing date
of this Information Disclosure Statement.

That <u>no</u> item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Attorney of Record David E. Wildman (Reg. No. 40226)

Telephone: (973) 235-6385 Telefax: (973) 235-2363

Substitute for form 1449A/PTO					Complete if Known							
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS (Use several sheets if necessary) MAR 0 9 2007							Application Number 10/815,			15,4	149	
						E	Filing Date		4/1/0	4/1/04		
						20	First Name Inventor Yvo (Gra	us	
						o 2007 %	10	Group Art Unit		1614		
						9 Z007 	Examiner Name					
Sheet	Sheet 1 of 1							Attorney Docket Number 21655 US2				
LIST ATENT DOCUMENTS												
		U.S. Patent Document										
Examine	er	Cite	Kind Code ²			Cind Code ²		Name of Patentee or Appl	icant o	f	Date of Publication of	
Initials'	I	No.1	Numbe	Number (if known)		,				Cited document MM-DD-YYYY		
		A2	2004/	2004/0018191					-		01-29-2004	
-	A2 2004/0018191		\dashv	Wang et al			01-29-2004					
-						ļ	4					
							_					
						ļ			_			
]						
-												
						1	寸					
							\dashv					
	\dashv					╁	ᅱ					_
	\dashv					 	ᅱ					
							\dashv					-
	\dashv		_			<u> </u>	4	 				
						<u> </u>						
	ı						'A '	TENT DOCUMENTS				
r	_	Cite No.1	Foreign Patent Document			ent		Name of Patentee or	Date of Publication of To			T⁵
Examine Initials'	SI		Office ³ Number WO 03/100008		hber Kind Coo		le ⁵	Applicant of Cited Docum			Cited Document MM-DD-YYYY	
	\dashv	B4			(if known)		Schering Corp		12-04-2003			
	B5 WO 03/059951			Medicament 07		U /	-24-2003					
								ļ				
												<u> </u>
												1
												
									_			1
							_		-			
												
Examine			Date Co	ongid-	rad		_	<u></u>	-+			L
Signatur			Date Co	onside	ıcu							

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

This is next communication to applicant.

Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.